---
layout: post
title: "Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development; Draft Guidance for Industry; Availability; Extension of Comment Period"
date: 2026-02-05 18:55:07 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-07185
original_published: 2023-04-06 00:00:00 +0000
significance: 8.00
---

# Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development; Draft Guidance for Industry; Availability; Extension of Comment Period

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** April 06, 2023 00:00 UTC
**Document Number:** 2023-07185

## Summary

The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice announcing the availability of a draft guidance for industry that appeared in the Federal Register of February 13, 2023. In that notice, FDA requested comments on the draft guidance for industry entitled "Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development." The Agency is taking this action to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/04/06/2023-07185/considerations-for-long-term-clinical-neurodevelopmental-safety-studies-in-neonatal-product)
- API: https://www.federalregister.gov/api/v1/documents/2023-07185

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
